Neuphoria Therapeutics Inc. (NEUP) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Neuphoria Therapeutics Inc. (NEUP) Healthcare & Pipeline Overview

Neuphoria Therapeutics, Inc., a clinical-stage biotech firm founded in 2024, concentrates on creating innovative treatments for neuropsychiatric disorders. With a focus on unmet needs, the company operates within the competitive pharmaceutical sector, marked by high research and development costs and stringent regulatory requirements.

What Is the Investment Thesis for NEUP?

Neuphoria Therapeutics presents a high-risk, high-reward investment opportunity characteristic of early-stage biotechnology companies. The company's focus on neuropsychiatric disorders addresses a significant unmet medical need, offering substantial market potential if its therapies prove successful. However, the company's negative P/E ratio of -0.06 and a profit margin of -4546.6% highlight its current lack of profitability and reliance on external funding. Key value drivers include successful clinical trial outcomes, strategic partnerships, and regulatory approvals. Upcoming catalysts include the progression of its lead drug candidates through clinical trials. Potential risks include clinical trial failures, regulatory setbacks, and funding constraints.

Based on FMP financials and quantitative analysis

NEUP Key Highlights

Market Cap of $20.2M reflects its early stage and potential for growth.

• Gross Margin of 94.7% indicates strong potential profitability upon commercialization, although it currently applies to limited or no product sales.
• Negative P/E Ratio of -0.06 signifies the company's current lack of profitability as it invests heavily in research and development.
• Profit Margin of -4546.6% highlights the significant expenses associated with clinical-stage drug development.
• Beta of 0.50 suggests lower volatility compared to the overall market, which may appeal to risk-averse investors.

Who Are NEUP's Competitors?

NEUP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NEUP's Key Strengths?

Focus on a high-need area of neuropsychiatric disorders.

• Innovative drug development approach.
• Experienced leadership team.
• Strong intellectual property potential.

What Are NEUP's Weaknesses?

Early-stage company with limited resources.

• High dependence on clinical trial outcomes.
• Lack of revenue generation.
• Limited market presence.

What Could Drive NEUP Stock Higher?

Initiation of Phase 2 clinical trials for lead drug candidate.

• Presentation of preclinical data at upcoming scientific conferences.
• Continued research and development efforts to expand the drug pipeline.

What Are the Key Risks for NEUP?

Financial-distress signal — its Altman Z-Score of -6.23 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Failure to secure adequate funding for research and development.
• Negative results from clinical trials.
• Regulatory delays or rejection of drug candidates.
• Competition from established pharmaceutical companies.
• Dependence on key personnel.

What Are the Growth Opportunities for NEUP?

• Advancement of Lead Drug Candidates: Neuphoria's primary growth opportunity lies in successfully advancing its lead drug candidates through clinical trials. Positive results from Phase 1, 2, and 3 trials would significantly increase the company's value and attract potential partnerships or acquisition offers. The timeline for this growth driver is dependent on the duration of clinical trials, which can range from several months to several years. The market size for successful neuropsychiatric drugs is substantial, potentially reaching billions of dollars annually.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions can provide Neuphoria with access to funding, expertise, and resources necessary to accelerate drug development. These collaborations can also help de-risk the development process and increase the likelihood of successful commercialization. The timeline for securing partnerships is uncertain, but ongoing efforts to network and present at industry conferences could yield results in the near term. The potential market impact of successful partnerships is significant, as it can lead to faster drug development and market access.
• Expansion into New Therapeutic Areas: While currently focused on specific neuropsychiatric disorders, Neuphoria could expand its research and development efforts into new therapeutic areas within the broader mental health space. This diversification could mitigate risk and create new revenue streams. The timeline for expanding into new therapeutic areas depends on the company's research capacity and funding availability. The market size for the broader mental health market is substantial, offering significant growth potential.
• Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA is a critical milestone for any pharmaceutical company. Successful approval of Neuphoria's drug candidates would allow the company to commercialize its products and generate revenue. The timeline for regulatory approval is dependent on the clinical trial results and the regulatory review process, which can take several years. The market impact of regulatory approval is transformative, as it allows the company to generate revenue and establish a market presence.
• Intellectual Property Protection: Strengthening its intellectual property portfolio through patents and other forms of protection is crucial for maintaining a competitive advantage. Strong IP protection can prevent competitors from copying Neuphoria's innovations and ensure the company's long-term market position. The timeline for securing intellectual property protection is ongoing, as the company continues to develop new technologies and formulations. The market impact of strong IP protection is significant, as it can create barriers to entry and ensure the company's long-term profitability.

What Are NEUP's Competitive Advantages?

• Proprietary drug formulations and technologies.
• Intellectual property protection through patents.
• Expertise in neuropsychiatric drug development.
• Potential first-mover advantage in specific therapeutic areas.

What Does NEUP Do?

Neuphoria Therapeutics, Inc., established on December 23, 2024, is a clinical-stage biotechnology company headquartered in Burlington, MA. The company is dedicated to the development of novel therapies targeting the intricate challenges presented by neuropsychiatric disorders. Neuphoria's mission is to improve the lives of individuals affected by these conditions through innovative pharmaceutical solutions. As a relatively new entrant in the biotechnology sector, Neuphoria Therapeutics is currently focused on advancing its pipeline of drug candidates through preclinical and clinical development stages. The company's strategy involves identifying and validating promising therapeutic targets, developing proprietary drug formulations, and conducting rigorous clinical trials to demonstrate safety and efficacy. Neuphoria's success hinges on its ability to navigate the complex regulatory landscape, secure funding for research and development, and ultimately bring its therapies to market. The company currently has 8 employees.

What Products and Services Does NEUP Offer?

• Develop novel therapies for neuropsychiatric disorders.
• Conduct preclinical and clinical research to evaluate drug candidates.
• Identify and validate promising therapeutic targets.
• Develop proprietary drug formulations.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approvals for its therapies.
• Potentially commercialize approved therapies.

How Does NEUP Make Money?

• Focus on research and development of pharmaceutical products.
• Generate revenue through potential future sales of approved therapies.
• Seek funding through venture capital, grants, and partnerships.
• Outsource manufacturing and other non-core functions.

What Industry Does NEUP Operate In?

Neuphoria Therapeutics operates within the highly competitive and rapidly evolving medical pharmaceutical industry. This sector is characterized by intense research and development, stringent regulatory requirements, and a constant drive for innovation. The market for neuropsychiatric disorder treatments is substantial and growing, driven by an aging population and increasing awareness of mental health issues. Neuphoria competes with established pharmaceutical giants and other emerging biotech companies, including ALZN, APRE, BCDA, BMRA, and CHEK, all vying for market share in this space.

Who Are NEUP's Key Customers?

• Patients suffering from neuropsychiatric disorders.
• Healthcare providers who prescribe medications.
• Hospitals and clinics that administer treatments.
• Pharmacies that dispense medications.

Company Profile

Neuphoria Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Burlington, US. The company is led by CEO Spyridon Papapetropoulos. NEUP has traded publicly since 2021.

Neuphoria Therapeutics Inc. Financial Trajectory

Neuphoria Therapeutics Inc. (NEUP) reported $0 in revenue for Q3 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $505K, with diluted EPS of $-0.09. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, NEUP averaged $-3.88 in diluted EPS.

How Neuphoria Therapeutics Inc. Is Valued

Neuphoria Therapeutics Inc. carries a market capitalization of $20.2M, placing it in the micro-cap category. Analyst price targets span from $7.00 to $7.00, with a consensus of $7.00. At the current price of $3.73, that implies approximately 88% upside potential. Relative to its peer group, NEUP's quantitative score of 31/100 is roughly in line with the peer average of 35/100.

Key Financial Metrics

Return on assets is -81.8%, showing how much profit it generates from its asset base. A current ratio of 14.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -140.0%, the inverse of the P/E and a quick read on earnings relative to price.

Neuphoria Therapeutics Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -6.23 places it in the distress zone, a signal of elevated financial risk.

Neuphoria Therapeutics Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 171.9% below estimates on average.

The most recent 11 insider filings for Neuphoria Therapeutics Inc. break down as 0 sales and 11 purchases. On net that is roughly 1.0M shares acquired (about $5.1M) — insiders putting money in tends to read as conviction.

NEUP Financials

NEUP Latest News

NEUP Analyst Consensus

NEUP MoonshotScore

Common Questions About NEUP (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources